Showing results (191-200 of 321) with videos related to

Sort By:
Pageof 33
International Journal of Radiation Biology|January 1, 1994
Manipulation and exploitation of the tumour environment for therapeutic benefitI J Stratford, G E Adams, J C Bremner, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
31P MRS to monitor the induction of tumor hypoxia by the modification of the oxygen affinity of hemoglobin using BW 589CR Kalra, J C Bremner, P J Wood, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugsE M Fielden, G E Adams, S Cole, et al.
British Journal of Cancer|June 23, 2000
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agentL H Patterson, S R McKeown, K Ruparelia, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2)Karen A Nolan, Mary C Caraher, Matthew P Humphries, et al.
FEBS Letters|March 18, 2014
The two common polymorphic forms of human NRH-quinone oxidoreductase 2 (NQO2) have different biochemical propertiesClare F Megarity, James R E Gill, M Clare Caraher, et al.
Journal of Medicinal Chemistry|January 10, 2003
Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylaseChristian Cole, Philip Reigan, Abdul Gbaj, et al.
European Journal of Medicinal Chemistry|September 13, 2019
Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2)Buthaina Hussein, Balqis Ikhmais, Manikandan Kadirvel, et al.
Bioorganic & Medicinal Chemistry|January 30, 2002
Synthesis and enzymatic evaluation of pyridinium-substituted uracil derivatives as novel inhibitors of thymidine phosphorylasePaul E Murray, Virginia A McNally, Stacey D Lockyer, et al.
Pageof 33